Abstract
Objective. Microtubule-associated protein 2 (MAP-2), a cellular protein restricted to neurons, is important in the control of cytoskeletal integrity and other neuronal functions. We undertook this study to examine the presence of autoantibodies to MAP-2 in neuropsychiatric systemic lupus erythematosus (NPSLE). Methods. Sera from 100 patients with SLE, 74 patients witli other neurologic disorders and injuries (including cerebrovascular accidents, brain trauma, brain tumors, and demyelinating disorders), and 60 normal controls were examined both by enzyme immunoassays and by Western immunoblotting for autoantibodies to MAP-2. Sera designated positive for antibodies to MAP-2 were required to be positive in both assays. Results. Seventeen percent of SLE patients had autoantibodies to MAP-2, in contrast to 4% of neurologic injury/disease control patients (P = 0.028) and 1.7% of normal controls. In SLE, anti-MAP-2 positivity in both assays was associated with neuropsychiatric symptoms in 76.5% of patients, whereas the absence of anti-MAP-2 was associated with neuropsychiatric symptoms in 19.7% of patients (P = 0.0002). The neuropsychiatric symptoms in the former group included psychosis, seizure, neuropathy, and cerebritis. Conclusion. Autoantibodies to MAP-2, a neuron-restricted cytoskeletal protein, appear to be another immune marker for NPSLE.
| Original language | English |
|---|---|
| Pages (from-to) | 1239-1247 |
| Number of pages | 9 |
| Journal | Arthritis and Rheumatism |
| Volume | 50 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 01-04-2004 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Rheumatology
- Immunology
- Pharmacology (medical)
Cite this
}
Antibodies to Microtubule-Associated Protein 2 in Patients With Neuropsychiatric Systemic Lupus Erythematosus. / Williams, Ralph C.; Sugiura, Kazumitsu; Tan, Eng M.
In: Arthritis and Rheumatism, Vol. 50, No. 4, 01.04.2004, p. 1239-1247.Research output: Contribution to journal › Article
TY - JOUR
T1 - Antibodies to Microtubule-Associated Protein 2 in Patients With Neuropsychiatric Systemic Lupus Erythematosus
AU - Williams, Ralph C.
AU - Sugiura, Kazumitsu
AU - Tan, Eng M.
PY - 2004/4/1
Y1 - 2004/4/1
N2 - Objective. Microtubule-associated protein 2 (MAP-2), a cellular protein restricted to neurons, is important in the control of cytoskeletal integrity and other neuronal functions. We undertook this study to examine the presence of autoantibodies to MAP-2 in neuropsychiatric systemic lupus erythematosus (NPSLE). Methods. Sera from 100 patients with SLE, 74 patients witli other neurologic disorders and injuries (including cerebrovascular accidents, brain trauma, brain tumors, and demyelinating disorders), and 60 normal controls were examined both by enzyme immunoassays and by Western immunoblotting for autoantibodies to MAP-2. Sera designated positive for antibodies to MAP-2 were required to be positive in both assays. Results. Seventeen percent of SLE patients had autoantibodies to MAP-2, in contrast to 4% of neurologic injury/disease control patients (P = 0.028) and 1.7% of normal controls. In SLE, anti-MAP-2 positivity in both assays was associated with neuropsychiatric symptoms in 76.5% of patients, whereas the absence of anti-MAP-2 was associated with neuropsychiatric symptoms in 19.7% of patients (P = 0.0002). The neuropsychiatric symptoms in the former group included psychosis, seizure, neuropathy, and cerebritis. Conclusion. Autoantibodies to MAP-2, a neuron-restricted cytoskeletal protein, appear to be another immune marker for NPSLE.
AB - Objective. Microtubule-associated protein 2 (MAP-2), a cellular protein restricted to neurons, is important in the control of cytoskeletal integrity and other neuronal functions. We undertook this study to examine the presence of autoantibodies to MAP-2 in neuropsychiatric systemic lupus erythematosus (NPSLE). Methods. Sera from 100 patients with SLE, 74 patients witli other neurologic disorders and injuries (including cerebrovascular accidents, brain trauma, brain tumors, and demyelinating disorders), and 60 normal controls were examined both by enzyme immunoassays and by Western immunoblotting for autoantibodies to MAP-2. Sera designated positive for antibodies to MAP-2 were required to be positive in both assays. Results. Seventeen percent of SLE patients had autoantibodies to MAP-2, in contrast to 4% of neurologic injury/disease control patients (P = 0.028) and 1.7% of normal controls. In SLE, anti-MAP-2 positivity in both assays was associated with neuropsychiatric symptoms in 76.5% of patients, whereas the absence of anti-MAP-2 was associated with neuropsychiatric symptoms in 19.7% of patients (P = 0.0002). The neuropsychiatric symptoms in the former group included psychosis, seizure, neuropathy, and cerebritis. Conclusion. Autoantibodies to MAP-2, a neuron-restricted cytoskeletal protein, appear to be another immune marker for NPSLE.
UR - http://www.scopus.com/inward/record.url?scp=1842783796&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1842783796&partnerID=8YFLogxK
U2 - 10.1002/art.20156
DO - 10.1002/art.20156
M3 - Article
C2 - 15077307
AN - SCOPUS:1842783796
VL - 50
SP - 1239
EP - 1247
JO - Arthritis and Rheumatology
JF - Arthritis and Rheumatology
SN - 2326-5191
IS - 4
ER -